1. Home
  2. DYN vs BNL Comparison

DYN vs BNL Comparison

Compare DYN & BNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYN
  • BNL
  • Stock Information
  • Founded
  • DYN 1984
  • BNL 2007
  • Country
  • DYN United States
  • BNL United States
  • Employees
  • DYN N/A
  • BNL N/A
  • Industry
  • DYN Medicinal Chemicals and Botanical Products
  • BNL Real Estate Investment Trusts
  • Sector
  • DYN Health Care
  • BNL Real Estate
  • Exchange
  • DYN Nasdaq
  • BNL Nasdaq
  • Market Cap
  • DYN 3.4B
  • BNL 3.4B
  • IPO Year
  • DYN 2020
  • BNL 2020
  • Fundamental
  • Price
  • DYN $28.39
  • BNL $17.19
  • Analyst Decision
  • DYN Strong Buy
  • BNL Hold
  • Analyst Count
  • DYN 9
  • BNL 7
  • Target Price
  • DYN $52.44
  • BNL $18.20
  • AVG Volume (30 Days)
  • DYN 1.0M
  • BNL 1.1M
  • Earning Date
  • DYN 11-12-2024
  • BNL 10-30-2024
  • Dividend Yield
  • DYN N/A
  • BNL 6.69%
  • EPS Growth
  • DYN N/A
  • BNL N/A
  • EPS
  • DYN N/A
  • BNL 0.75
  • Revenue
  • DYN N/A
  • BNL $424,671,000.00
  • Revenue This Year
  • DYN N/A
  • BNL N/A
  • Revenue Next Year
  • DYN N/A
  • BNL $4.12
  • P/E Ratio
  • DYN N/A
  • BNL $22.84
  • Revenue Growth
  • DYN N/A
  • BNL N/A
  • 52 Week Low
  • DYN $9.82
  • BNL $14.21
  • 52 Week High
  • DYN $47.45
  • BNL $19.15
  • Technical
  • Relative Strength Index (RSI)
  • DYN 42.04
  • BNL 36.93
  • Support Level
  • DYN $27.99
  • BNL $16.87
  • Resistance Level
  • DYN $35.68
  • BNL $17.82
  • Average True Range (ATR)
  • DYN 2.09
  • BNL 0.38
  • MACD
  • DYN 0.23
  • BNL -0.06
  • Stochastic Oscillator
  • DYN 9.12
  • BNL 21.55

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

About BNL Broadstone Net Lease Inc.

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

Share on Social Networks: